Phase 1/2RecruitingAge-related condition

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

A Multicenter, Dose-escalation and Dose-expansion, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy Characteristics of SCT520FF in Patients With Neovascular Age-related Macular Degeneration

Sponsor
Sinocelltech Ltd. (Industry)
Enrollment
82 planned
Conditions
nAMD
Interventions
SCT520FF; SCT520FF; SCT520FF; EYLEA 2 MG
Ages
adults, older adults
Registry
NCT06672536

Full record on ClinicalTrials.gov

From the registry

Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.

Primary outcomes

  • Treatment emergent adverse events(TEAE)
  • Treatment-related treatment emergent adverse events(TRAE)
  • Serious adverse event(SAE)
  • Adverse event of special interest(AESI)

History

  1. Study completion expected

  2. Primary completion

  3. Last registry update

  4. Started

  5. Registered